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Abstract  
Introduction: Pazopanib, a multi-target tyrosine-kinase inhibitor (TKI), is a relatively novel anticancer agent registered for 
advanced renal cell carcinoma recently emerged in the setting of advanced soft -tissue sarcoma (STS). In the early clinical 
trials pazopanib has been very marginally linked to left ventricular ejection fraction (LVEF) dysfunction as, on contrary, 
reported for other anti-angiogenesis TKIs, such as Sunitinib and Sorafenib.  
Presentation of Case: We here present a case of severe, but reversible, congestive cardiac failure in a 37-year old Caucasian 
man affected by soft-tissue sarcoma during an efficacious treatment with pazopanib. 
Conclusion: Cardiac damage from novel TKI treatments is still an underestimated phenomenon. In our patient, pazopanib 
was the only treatment ensuring stability of disease and its discontinuation meant disease progression. Post -approval 
monitoring of novel TKIs should be taken into account by clinicians including a careful monitoring of LVEF and all 
symptoms suggestive of cardiac dysfunction, in particular for drugs potentially capable to change the natural history of still 
uncurable cancer. 
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Introduction 
Multikinase tyrosine-kinase inhibitors (TKIs), such as Sunitinib and Sorafenib, targeting angiogenesis 
and cancer cell proliferative signals, have been introduced with encouraging results in the settings of 
renal cell carcinoma (RCC) and hepato-cellular carcinoma (HCC), while their impact in soft-tissue 
sarcoma (STS) has been negligible [1,2]. However, angiogenesis plays an important role in STS and 
vascular-endothelial growth factor (VEGF) correlates with tumor stage, grade and clinical outcome. 
Similarly, platelet-derived growth factor-β (PDGF-β) signaling appears to be related to tumor grade and 
cell proliferation [3]. 
 
Pazopanib is a multi-target TKI anti-VEGFR 1-2-3, -PDGFR α-β, -c-kit and others registered for 
advanced RCC [4,5]. From phase I, II and III clinical trials it has emerged that Pazopanib is also the 
first TKI targeting angiogenesis showing a simultaneous activity in advanced STS [6-8]. In these early 
clinical trials, the clinicians recognized evidence of side effects mostly related to liver and gastro-enteral 
toxicities and pazopanib has been marginally considered for LVEF dysfunction as, on contrary, reported 
for Sunitinib and Sorafenib [9-11].  
Generally, TKIs cardiotoxicity can be “on target” when the factor promoting cancer cells survival 
plays also a functional role in normal cardiac cells, while “off target” TKI toxicity, such as the one of 
pan-TKIs, is generally related to their lack of selectivity. In these latter cases, the inhibition of a target 
not specifically responsible for cancer cell survival is causing cardiotoxicity, due to its functional 
presence on cardiac cells [12-14].
 
ABL inhibitor Imatinib, principally developed for chronic 
myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) treatment, represents an 
example of “on target” cardiotoxicity. The pivotal trials on imatinib did not show significant rates of 
cardiotoxicity or did not include cardiac function monitoring [15-17] Nevertheless, it has been 
subsequently reported that patients treated with imatinib could develop severe CHF [18], and Kerkela et 
al. described a significant left ventricular (LV) dysfunction arisen in 10 patients during treatment with 
imatinib [19], suggesting that ABL activity could play a role in cardiomyocytes survival.  
Multi-target TKIs are expected to determine “off target” effects due to the lack of selectivity [12]. 
Sunitinib is a TKI inhibiting VEGFR1-3, PDGFRα-β, c-KIT and other TKs approved for advanced 
RCC and GIST [20]. Similarly, Sorafenib, a cell surface kinase receptors (VEGFR2-3, PDGFR-β, 
c-KIT) inhibitor, additionally targeting RAF kinases (CRAF, BRAF), is approved for the treatment of 
unresectable HCC and for advanced RCC. In an observational study, Schmidinger et al described an 
overall 33,8% incidence of cardiovascular events in 74 patients with mRCC treated with Sunitinib or 
Sorafenib after a median duration treatment of 8 weeks. This study outlined that cardiac events caused 
by these agents are more frequent than it has been reported in clinical trials [21], suggesting the need of 
a careful monitoring of heart failure in these settings. Based on this background, we here report a case 
of reversible decompensated heart failure in a patient with a soft tissue sarcoma (STS) briefly treated by 
a relatively new TKI, such as pazopanib. 
Case Presentation 
On December 2011 a 37-years old patient underwent right forearm amputation for a high-grade 
epithelioid sarcoma (pT2a N0 M0 R0 stage II), followed by six cycles of adjuvant chemotherapy with 
standard doses of Epirubicin plus Ifosfamide (Epirubicin 90 mg/m
2
, total dose 180 mg each cycle, 
cumulative dose 1080 mg; Ifosfamide 2,5 gr/m
2, 
total dose 5 gr each cycle, cumulative dose 30 gr). In 
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June 2012, CT/PET scan and ultra-sound (US) revaluation showed bilateral multiple lung metastases 
(Fig.1A) and a subcutaneous stump recurrence. A first-line treatment with Trabectedin (1,5 mg/m
2
 in 
24h 3w; total dose 3 mg each cycle) was then introduced and, after 3 cycles, a CT scan showed a local 
stump and pulmonary progression (not shown). Despite the lack of symptoms, a brain magnetic 
resonance (MRI) additionally showed two encephalic metastatic lesions (Fig.1B, left panel). 
Trabectedin was then discontinued and, in December 2012, following stump pain onset, he underwent 
local fractioned radiotherapy (total dose 20 Gy in 5 fractions). At that time, on physical examination, 
the patient was in good general condition, vital signs were within normal range and an echocardiogram 
revealed a left ventricular ejection fraction (LVEF) of 55% An additional movie file shows this. [See 
Additional file 1, Video Sequence 1].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 (A) From left to right, lung CT-scans on July 2012, November 2012, February 2013 and April 2013. 
(B) From left to right, brain MRI on December 2012, brain CT-scan in January 2013, February 2013 and April 
2013. Arrows identify target lesions observed during pazopanib treatment and discontinuation. 
 
On 13
th
 December 2012 a treatment with pazopanib 800 mg/die was initiated. After 30 days, a brain 
CT-scan showed stable disease that was then further confirmed after 60 days (Fig.1B, middle panels). 
Similarly, a lung CT-scan revealed the stability of pulmonary lesions, and in some cases a central 
cavitation as a further indicator of a TKIs response (Fig.1, third panel from the left) [22,23].  
Pazopanib treatment was maintained for 60 days and was only briefly discontinued due to low platelets 
counts (Grade II) in relation with the hemorrhage risks for central nervous system (CNS) metastases.  
In a further physical examination, on day 75, the patient reported dyspnea on exertion and legs 
swelling. The ECG was normal, as well as blood tests (including troponine-I serical levels) and chest 
x-ray. The patient was admitted for further examination and an echocardiogram showed a significant 
reduction in the contractile function of the left ventricle with severe and diffuse hypokinesia with an 
estimated LVEF of 30% [see Additional file 1, Video Sequence 2]. A diagnose of acute heart failure was 
made and pazopanib treatment definitively discontinued. Patient was then prescribed comprehensive 
therapy including diuretics, β-blockers and ACE inhibitors. In mid-March the patient’s symptoms and 
signs of heart failure resolved and an echocardiogram performed on 18
th
 March 2013 showed an 
A 
B 
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increase of LVEF (45%) [see Additional file 1, Video Sequence 3]. On April 2013 a total body CT-scan 
showed an increase in size of the encephalic lesions and abundant peripheral edema (Fig.1B, right 
panel). These lesions became rapidly symptomatic with seizure controlled by anti-epileptic medical 
therapy and whole-brain radiotherapy (WBRT) (30 Gy in 10 fractions) followed by Gemcitabine (1000 
mg/ m
2
 days 1,8). At the last follow up the echocardiogram showed a further amelioration of the LVEF 
(55%; not shown) versus the latest evaluation with no sings and symptoms of cardiac failure. 
Discussion  
Because of their specificity for TK receptors in tumor cells, targeted therapies by TKIs were supposed 
to be less cardiotoxic than conventional chemotherapy.  However, only after their extensive use, a 
certain degree of cardiotoxicity has been emerging. The impact of TKI-related cardiotoxicity is still 
largely underestimated for two main reasons, on one side clinical trials do not generally include cardiac 
endpoints or LVEF assessment and on the other differentials of heart failure in cancer patients may be 
confounding since it may be related to other etiologies [12,13]. 
Pazopanib has been recently introduced in STS treatment with no relevant cardiotoxicity in phase I-II 
trials [7,8]. However, cardiotoxicity seemed to emerge in the PALETTE trial with a drop in LVEF 
observed in 3,8% patients in the pazopanib arm and of those only 1,2% were symptomatic. Nevertheless, 
in the placebo group the incidence was not dissimilar (2,4%), and the lack of a dedicated statistical 
analyses does not clarify the issue. Collectively, these early findings indicate the need of more attention 
for this complication in patients that were almost all (99%) pre-treated by anthracyclines as a further 
risk factor.  
To our knowledge, there are no reports describing such a direct impact of pazopanib on cardiac 
function and the timing of occurrence in severe CHF during treatment with pazopanib has not been 
carefully assessed so far. Very recently, a trial evaluating the effect of repeated doses of pazopanib on 
cardiac conduction has been published. This study showed that pazopanib produced a 
concentration-independent prolongation in the QTc interval [24]. Curiously, considering retrospectively 
the ECG tracings in our patient over time, we also have to report a tendency to prolongation of QTc 
(from 449 ms of December 2012 to 478 ms of February 2013).  
In general, TKIs cardiotoxicity has shown to be increased in patients with coronary risk factors, prior 
LV dysfunction and prior or concomitant use of anthracyclines. Our young patient had only the 
predisposing condition of anthracyclines pre-treatment. However, in this case LVEF was normal before 
starting pazopanib and strict clinical monitoring was performed during the treatment, without observing 
any abnormalities. Moreover, after the definitive discontinuation of Pazopanib and the introduction of 
the comprehensive cardiac therapy, the LVEF returned rapidly in range. 
The mechanisms of myocardial damage by TKIs have not been fully investigated but some 
hypothesis has been advanced. These agents target the Von-Hipple-Lindau hypoxia-inducible (HIF) 
gene pathway. Therefore, HIF-1 related gene products seem to be mediators of response to cardiac 
damage, secondly VEGF-VEGFR inhibition could be relevant in patients with poorly controlled 
hypertension because VEGF is essential in maintaining a normal response of cardiomyocytes to 
pressure overload [25]. Very recently Chintalgattu et al showed that vascular perycites are the primary 
cellular target of Sunitinib-induced cardiotoxicity, highlighting the role of PDGFR in pericyte survival 
[26]
.
 This hypothesis may also justify the observed reversible impact of pazopanib in cardiac damage, 
due to the capacity of vascular perycites to self-regenerate simultaneously supporting myocardial tissue 
[27]. 
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Conclusion 
In summary, cardiac damage from TKI treatment is still an underestimated phenomenon that require 
further investigations; rates of cardiac heart failure can be expected to be higher than in the highly 
selected population of patients of phase I-II trials and doses adjustments shall be careful considered 
based on predisposing conditions. Thus, post-approval monitoring should be taken into account by 
clinicians, monitoring carefully LVEF and all the symptoms suggestive of cardiac dysfunction, in 
particular for drugs potentially capable to change the natural history of still uncurable cancer, such as 
STS.  
Consent  
Written informed consent was obtained from the patient for publication of this Case Report and any 
accompanying images. A copy of the written consent is available for review by the Editor of this 
journal. 
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